pharmaphorum

OCTOBER 8, 2020

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. Scribe has designed, engineered and tested thousands of evolved CRISPR enzymes to build an advanced platform for creating breakthrough in vivo treatments,” said Oakes.

Gene Editing 54

Gene Editing Gene In-Vivo Clinical Trials 54

Drug Discovery World

MAY 5, 2023

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. In contrast to DNA-based reprogramming and gene editing, the mRNA-based approach does not expose cells to expensive and potentially harmful viruses or DNA vectors.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Drug Discovery World

JULY 18, 2023

The centre also features a newly built demo lab which will bring the Revvity portfolio closer to scientists.

Genome 52

Genome Genomics Life Science Gene Editing 52

BioPharma Reporter

MARCH 2, 2021

The gene-editing and genome-engineering company, eGenesis, today announced the completion of a US$125m Series C financing round.

Gene Editing 52

Gene Editing Medicine Genome Genomics 52

WCG Clinical

NOVEMBER 17, 2023

This change expanded the definition of HGT research to include research using nucleic acids that are able to replicate, be transcribed, translated into protein, and/or integrate into the host genome. Since then, however, certain genetic engineering technologies (e.g., Since then, however, certain genetic engineering technologies (e.g.,

Genome 52

Genome Genomics Gene Editing Genetic Engineering 52

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Scienmag

JANUARY 5, 2022

SAN FRANCISCO, CA—January 5, 2021—Over the past decade, the CRISPR genome-editing system has revolutionized molecular biology, giving scientists the ability to alter genes inside living cells for research or medical applications. Credit: Photo: Michael Short/Gladstone Institutes […].

Gene 87

Gene Gene Editing Research Genome 87

Drug Discovery World

OCTOBER 10, 2023

The National Institutes of Health has awarded the first phase of a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases. The two diseases being targeted in the project are Angelman syndrome and H1-4 (HIST1H1E) syndrome.

Gene Editing 52

Gene Editing Development Drugs Clinical Trials 52

Drug Discovery World

NOVEMBER 27, 2023

Upstream cell line development has seen notable progress with recent advances in cell line engineering, particularly in enhancing gene of interest integration specificity, clone selection, and production efficiency. Next-generation engineering tools, such as gene editing have enabled knock-out cell lines with enhanced characteristics.

Production 59

Production Engineer Gene Editing Gene 59

Drug Discovery World

NOVEMBER 1, 2023

DDW’s Diana Spencer meets Dr Stephen Jones, Research Professor and Group Leader at the EMBL Partnership Institute for Genome Editing Technologies at Vilnius University’s Life Sciences Center. DS: Can you tell us what you do and what you’re working on at the moment? DS: What’s been the highlight of your career so far?

Gene Editing 59

Gene Editing Research Gene Genome 59

Drug Discovery World

JUNE 22, 2023

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights.

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

Drug Discovery World

DECEMBER 12, 2022

Dr Ramakrishnan, who holds a Bachelor of Biotechnology and Biochemical Engineering from the University of Kerala in India, presented a proposal examining microbiome-based therapeutics for asthma. . The study advances our understanding of ADHD by showing how the condition is tied to changes in how certain genes are expressed in the brain.

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

JANUARY 24, 2021

Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering. Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. ” Chris Bond , Ph.D.,

Engineer 52

Engineer Gene Editing Genome Genomics 52

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . Limitations of organoids.

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

pharmaphorum

AUGUST 25, 2022

Explore approaches to boost safe gene-editing, approach regulatory affairs, turbocharge scale-up, optimize analytics and more to produce best-in-class therapies for immuno-oncology and regenerative medicine. Sana Biotechnology , Takeda and many more.

Gene Editing 40

Gene Editing Genome Genomics Engineer 40

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 57

Gene Editing Genome Genomics Engineer 57

Drug Discovery World

DECEMBER 15, 2022

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukemia (AML). .

Drugs 52

Drugs Genome Genomics Engineer 52

The Pharma Data

SEPTEMBER 1, 2021

Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. The engineered cells reduced inflammation and prevented a type of damage to bone, known as bone erosion, in a mouse model of rheumatoid arthritis. ” The new findings are published online Sept.

Drugs 52

Drugs Engineer Drug Delivery Gene 52

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

XTalks

MARCH 28, 2024

Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment. For example, gene editing can possibly be used to correct cancer-causing mutations or enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

The Pharma Data

FEBRUARY 22, 2021

Gene editing investments advance agriculture with improved food quality, higher yield, and improved crop nutrition. Gene editing is the key to better solutions and greater choices for farmers and consumers around the world. This enhances sustainability and helps us reduce the environmental impact of agriculture.”.

Gene Editing 40

Gene Editing Genome Genomics Protein 40

Cloudbyz

MARCH 6, 2024

With ongoing innovations in biotechnology, genomics, and computational biology, we can expect to see further refinement of biologic therapies, as well as the emergence of novel treatment modalities that harness the power of biological systems to combat disease.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

Drug Discovery World

DECEMBER 12, 2022

The meeting will focus on the application of genome engineering in identification of novel drug targets through large-scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and its applications in therapeutic genome editing. Register here.

Genome 52

Genome Genomics Engineer In-Vivo 52

XTalks

JULY 14, 2022

CRISPR-Cas9 gene editing was used to simultaneously perturb thousands of genes by targeting specific points of genetic code. The focus was on genes that create transcription factors , which are proteins that switch genes on or off and therefore control multiple other genes at once, including the three immune factors of interest.

Gene 98

Gene Regulation Protein Gene Editing 98

Delveinsight

SEPTEMBER 14, 2021

Vor Biopharma has declared that the FDA has awarded their acute myeloid leukemia (AML) engineered hematopoietic stem cell therapy (eHSC), VOR33, a Fast Track Designation. VOR33 comprises CRISPR genome-edited hematopoietic stem and progenitor cells , which have been engineered to exclude CD33.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

XTalks

NOVEMBER 30, 2023

In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs). In addition, Vir Biotechnology, Inc.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Delveinsight

AUGUST 27, 2020

Freenome’s diagnostic searches for direct indication of tumors and signs of the immune system’s response, integrating genomics, transcriptomics, methylomics, and proteomics technologies. Targeted drug combo attacks breast cancer brain metastases in mice. White fat, in contrast, can build up and cause obesity.

Vaccination 53

Vaccination Vaccine Research Trials 53

Drug Discovery World

OCTOBER 16, 2023

Maina Bhaman, Partner at Sofinnova Partners, says: “The UK is an attractive space for drug discovery companies and a prime environment for investment due to its talent, infrastructure, and genomics research. Revvity has its own research team based in Cambridge, as well as cell line engineering and drug screening services, and bioproduction.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Roots Analysis

FEBRUARY 15, 2022

Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. Genome Editing is a way of making changes in the DNA.

Genome 52

Genome Genomics Gene Editing DNA 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 91

Gene Editing Gene DNA Engineer 91

Delveinsight

FEBRUARY 25, 2021

The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site. Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing.

DNA 52

DNA In-Vivo Genetics Medicine 52

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 13, 2023

About 30% of epilepsy patients do not respond to available anti-seizure treatments, says Dr. Dario Englot, director of functional neurosurgery at Vanderbilt University’s Institute for Surgery and Engineering in Nashville, Tennessee. In his work, Ferraro focuses on the links between gene variations and different responses to drugs.

Research 264

Research Gene Gene Therapy Genome 264

XTalks

AUGUST 29, 2022

Now a common gene editing tool, the popularity of the CRISPR-Cas9 system has increased over the past decade. CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome. Harnessing the Cellular Engineering Potential of CRISPR.

Gene Editing 98

Gene Editing DNA Gene Genome 98

XTalks

DECEMBER 20, 2023

CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason. Given its ability to precisely edit genes, there is tremendous promise for the revolutionary technology to offer cures for genetic disorders and to treat various diseases.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Drug Discovery World

JANUARY 23, 2023

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. In addition, iPSC lines, despite their pluripotency, have skewed suitability towards certain cell types 12,13.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics 52

Genetics Research Medicine Clinical Research 52